Introduction: There is an urgent need to develop new treatments for Alzheimer's disease (AD) and to understand the drug development process for new AD therapies. 
Alzheimer's disease (AD) is increasing rapidly in frequency as the world's population ages and more people enter the major risk period for this age-related disorder. From the 5.3 million US citizens affected now, the number of victims will increase to 13 million or more by 2050; worldwide the total number of affected individuals will increase to a staggering 100 million [1] . The cost of care in the US, currently more than $200 billion annually, will grow to an unsupportable $1 trillion annually by 2050 [1] . New therapies are urgently needed to treat affected patients and to prevent, defer, slow the decline, or improve the symptoms of AD. It has been estimated that the overall frequency of the disease would be decreased by nearly 50% if the onset of the disease could be delayed by 5 years [2] . Symptomatic treatments are drugs aimed at cognitive enhancement or control of neuropsychiatric symptoms and typically work through neurotransmitter mechanisms; disease-modifying therapies or treatments (DMTs) are agents that prevent, delay, or slow progression and target the underlying pathophysiologic mechanisms of AD [3] . To understand the progress of drug development, describe the timelines regarding when drugs could become available, and interrogate the current drug development approaches for AD treatments, we examined the AD drug development pipeline as currently revealed in clinicaltrials.gov. We present our findings as a means of understanding and ultimately improving AD drug development. This paper continues the themes developed in our 2016 pipeline report [4] and impacts the understanding of the likelihood of reaching the national goal of having meaningful therapy for AD by 2025 [5] .
Methods
Clinicaltrials.gov includes a comprehensive list of all clinical trials of AD and describes the trial features in text form. The "Common Rule" governing clinicaltrials.gov was updated in 2016 [6, 7] . Registration is mandated for all trials from sponsors with an Investigational New Drug or Investigational New Device. Trials must be submitted to the site within 21 days of the enrollment of the first trial participant. Results must be submitted to clincaltrials.gov within 12 months of completion of final data collection for the prespecified primary outcome measures; clinicaltrials. gov can be regarded as a comprehensive resource for the study of clinical trials governed by the US Food and Drug Administration (FDA) or the National Institutes of Health (NIH). Not all non-US trials are registered on clinical trials.gov-especially phase I trials. We also cannot attest to compliance with the rule governing clinicaltrials.gov, and some agents may not be registered or sponsors may not adhere to required timelines.
We examined clinicaltrials.gov as of January 5, 2017 . We captured all trials of all agents in phases I, II, and III. In a comprehensive database, we entered the trial title, beginning date, projected end date, calculated duration, number of subjects planned to be enrolled, number of arms of the study (usually a placebo arm and one or more treatment arms with different doses of the experimental agent), whether a biomarker was described, and sponsorship by a biopharma company, NIH, academic medical center, "other" entity such as a consortium or a philanthropic organization, or a combination of the aforementioned sponsors. We included trials that were recruiting, active but not recruiting (e.g., trials that have completed recruiting and are continuing as the efficacy or safety of the agent is being determined), enrolling by invitation, and not yet recruiting. We did not include trials listed as completed, terminated, suspended, or withdrawn. Information on these trials or the reasons for suspension or termination is often incomplete. The choice of types of trials included was informed by our intention of understanding the currently active pipeline and to know what agents could evolve in the near term. We did not include trials of nonpharmacologic therapeutic approaches such as devices, cognitive therapies, and medical food. We did not include trials of biomarkers.
The mechanism of action (MOA) of each agent was determined from the information on clinicaltrials.gov (e.g., the mechanism is often noted in the title of the trial or in a description of the trial) or from a comprehensive search of the literature if the mechanism was not provided on the federal website. In a few cases, the mechanism is undisclosed and could not be identified in the literature. We grouped the mechanisms into symptomatic agents or DMTs. We divided the symptomatic agents into those that are putative cognitive enhancing agents or those that address neuropsychiatric and behavioral symptoms. DMTs were divided into those that target amyloidrelated mechanisms, those that have tau-related MOAs, and those with "other" mechanisms such as anti-inflammatory MOAs, growth factors, or metabolic effects. Stem cell therapies were included in the "other" category. Fig. 1 provides an overview of all agents currently in the AD pipeline. The circles reveal the stages of development (I, II, and III), the colors pertain to the MOA of the agent, and the shape denotes the population in which the agent is being tested (normal volunteers, cognitive normal at-risk individuals, prodromal AD, and AD dementia).
Results

Overview
In all, there are 105 agents in the pipeline as shown on clinicaltrials.gov, of which 25 are agents in 29 trials in phase I, 52 agents are in 68 trials in phase II, and 28 agents are in 42 trials in phase III. Across all stages, 70% are DMTs, 14% are symptomatic cognitive enhancers, 13% are symptomatic agents addressing neuropsychiatric and behavioral changes, and 2% have undisclosed MOAs.
Of all trials, 65.5% are sponsored by the biopharma industry, 16.6% by Academic Medical Centers, 3.6% by Academic Medical Center-NIH collaborations, and 10.8% by the collaborations between consortiums/philanthropic organizations and one or more of the following: biopharma, NIH, and Academic Medical Centers. One trial is sponsored by NIH, one trial by biopharma-NIH collaboration, and one trial by a biopharma-NIH-Academic Medical Center collaboration.
Phase I
Phase I first-in-human trials are generally conducted in healthy volunteers unless they are assessing immunotherapies where the potential long-term modification of the immune system makes participation of normal controls impermissible. These trials generally progress from single ascending dose trials where increasing doses are administered once in supervised settings to assess tolerability and establish a maximum tolerated dose to multiple ascending dose trials where individuals receive doses for 14 to 28 days [8] [9] [10] . Single and multiple ascending dose studies typically include cohorts of 6 to 12 individuals assigned asymmetrically to drug or placebo (e.g., four on placebo and eight on drug in a 12-person cohort). The goal of phase I trials is to assess the safety and tolerability of the agent, identify the doses to be advanced to phase II, and document the pharmacokinetics (PK) of the drug (e.g., half-life, time to maximum serum concentration [T-max], maximum serum concentration for each dose [C-max], bioavailability, dose-blood level linearity, etc). PK studies are conducted in animals before phase I but must be repeated in the firstin-human setting to establish the PK characteristics specific to men and women. Food effects on drug absorption and drug-drug interactions are also assessed in phase I studies. A cohort of healthy elderly is often included to assess the effect of age on PK parameters. In phase I/II studies, a cohort of individuals with AD may be included.
Of the 24 agents whose MOA was revealed in phase I in 2017 ( Fig. 1; Table 1 ), 12 were directed at amyloid-related targets including eight immunotherapies, three had taurelated MOAs, and nine had other mechanisms including four symptomatic cognitive enhancers. Overall, there were 20 DMTs and four symptomatic agents in phase I. The MOA was not revealed for one agent.
Phase I trials were on average 755 days in duration (recruitment and treatment period) and involved 68 patients in each trial.
Phase II
Phase II trials advance the agents from phase I to trial populations of patients with AD. The goal of these trials is to establish preliminary efficacy based on a biomarker outcome, a clinical measure, or a combination of clinical and biomarker outcomes [11, 12] . Phase IIa trials concentrate on efficacy, and phase IIb trials further refine dosing decisions about the number of doses to be advanced to phase III. Of the 68 trials in phase II of the AD pipeline, 21 included patients with prodromal or prodromal and mild AD, 26 were trials for mild-moderate AD, one included patients with prodromal or mildmoderate AD, and one trial was for mild-moderate or severe AD. Of the symptomatic trials, 10 were for mild-moderate AD and six were for mild-moderate or severe AD. On average, phase II trials were 1140 days in duration (recruitment plus exposure period) and involved 151 patients in each trial.
Of the 52 agents in the 68 trials, there were 36 DMTs, eight cognitive enhancing agents, seven drugs for behavioral symptoms, and one agent with an unknown MOA ( Fig. 1; Table 2 ). Among the DMTs, 14 addressed amyloid targets, four involved tau-related targets, one addressed both amyloid and tau-related targets, and 17 had other MOAs (e.g., metabolic, or antiinflammatory). The DMTs include six immunotherapies (four addressing amyloid and two addressing tau). Of the DMTs, 17 are repurposed agents approved for use in another indication. There are seven trials involving stem cell programs.
Of the drugs with amyloid targets, there were three b-site amyloid precursor protein cleaving enzyme (BACE) inhibitors, four immunotherapies, and eight anti-aggregation agents. Fig. 2 shows the MOAs of agents in phase II.
Phase III
Phases II and III trials are often called "learn" and "confirm" trials, respectively, with phase III intended to confirm effects observed in phase II in larger populations treated for longer periods of time [11, 13] . In addition to providing crucial efficacy data, phase III trials also provide exposure data on larger numbers of patient-days essential to establishing the safety and tolerability of the candidate therapy.
Of the 28 agents in the 42 trials, there were 18 DMTs, three cognitive enhancing agents, and seven drugs for behavioral symptoms. Among the DMTs, 15 addressed amyloid targets, one involved a tau-related target, and two had a metabolic MOA. The DMTs include six immunotherapies (all addressing amyloid). Of the DMTs, four are repurposed agents approved for use in another indication. Of the drugs with amyloid targets, there were five BACE inhibitors, six immunotherapies, and four anti-aggregation agents. Table 3 shows the agents currently in phase III of AD drug development. Fig. 3 shows the MOAs of agents in phase III and Fig. 4 shows an illustration of the drug mechanism of phase III agents and the proposed biology of AD.
Among the DMT trials, there were five prevention trials enrolling cognitively normal participants at high risk for developing AD in the course of the trials; 14 trials of patients with prodromal AD (those with minimal cognitive symptoms and a biomarker indicative of AD-related brain changes) or prodromal/mild AD; and nine trials of patients with mild-moderate AD.
On average, phase III trials involved 1012 patients and were 1677 days in duration (including the recruitment and the treatment period 
Participant numbers
Recruitment is the slowest and most expensive aspect of clinical trials [14] . The period of recruitment may exceed the period of treatment in the clinical trial cycle. The total number of participants needed to populate all clinical trials for AD is large. Table 4 shows the number of participants needed for all current prevention trials, phase I, phase II, and phase III trials.
Biomarkers
Biomarkers have many roles in clinical trials including identifyingpatients for trials andverifyingdiagnosis,assessingtarget engagement and providing proof of pharmacology, serving as outcomes for DMT trials, and assessing side effects (e.g., monitoring amyloid-related imaging abnormalities [ARIAs] observed with some immunotherapies) [14] [15] [16] [17] . ARIA has emerged as a concern in several major immunotherapy development programs-bapineuzumab, gantenerumab, and aducanumab. Although largely asymptomatic, these changes can lead to permanent neurologic sequelae and will be a focus of research once the efficacy of the immunotherapies is established. Preliminary evidence suggests that longer dose titration periods may decrease the risk of ARIAs [18] .
Not all trial descriptions in clinicalrials.gov note if biomarkers are used. Table 5 shows the biomarkers used as outcome measures in current phase II and phase III AD clinical trials as included in the federal website. Of the 28 phase III DMT trials, 10 trials use amyloid positron emission tomography (PET) as an entry criterion, two use cerebrospinal fluid (CSF) amyloid, and two use either amyloid PET or CSF amyloid. Thirteen out of 46 phase II DMT trials used amyloid-PET as an entry criterion.
Comparison to 2016 pipeline
In any 1-year period, there is relatively little movement in the AD pipeline. Compared to 2016, there are eight new agents in phase I, 16 in phase II, and five in phase III. Of the new agents in phase II, three of the 16 were previously Table 3 Agents present in phase I (AADvac1, CT1812, and LY3202626). Of the new agents in phase III, two of the five were previously noted in phase II (crenezumab and E2609).
Agents can appear in phase II without having been listed in phase I because the phase I study was not done in the US and was not registered on clinicaltrials.gov or because they are repurposed agents that had the PK and dosing established through trials for a non-AD indication [15, 19, 20] . Rarely, a repurposed agent can enter directly into phase III without a phase II trial. In the AD pipeline, there are 18 repurposed agents in phase II and nine in phase III.
Seven agents were listed in phase II in 2016 and are not listed in phase I, II, or III in 2017. These agents have at least temporarily exited the drug development pipeline. Four trials for the following agents were completed in 2016 but are not listed in the 2017 pipeline: exenatide, PXT00864, RO4602522, and RPh201. Two trials were terminated (MK-7622 and PF-05212377), and the trial status for metformin changed to "unknown" because it has not been updated for more than 2 years on clinicaltrials.gov.
One agent (masitinib) was listed in phase III in 2016 and is not listed in phase I, II, or III in 2017. Its trial status changed to "unknown" because it has not been updated on clinicaltrials.gov since 2013. Development of this agent has been at least temporarily interrupted.
Candidate agents that are no longer evident in the pipeline may have failed to demonstrate efficacy in well-conducted trials, they may have failed to show efficacy in trials whose features suggest the trials were not well conducted, or there may be industry reasons for halting the program (e.g., insufficient funding, reprioritization of agents in development, change in company business agenda, and management decision after assessment of the competitive landscape) [21] .
Discussion
There is a modest pipeline of drugs in development for AD. Most candidate therapies are DMTs (70% across all phases), and the remainder are symptomatic agents directed at cognitive enhancement (14%) or treatment of neuropsychiatric symptoms (13%) and agents with undisclosed MOAs (2%). This closely resembles the pipeline as it appeared in 2016 where 73% were DMTs, 18% cognitive enhancers, and 9% psychotropic agents [4] . There are eight new agents in phase I, 16 in phase II, and five in phase III. From the 2016 pipeline, several agents have exited and not yet reappeared including six in phase I, seven in phase II, and one in phase III. Leuco-methylthioninium (LMTM) (or TRx0237) derived from methylene blue and addressing tau aggregation completed its phase III trials in 2016 and failed to meet prespecified outcomes of the trial [22] ; however, its open-label extension study is listed as ongoing.
The shortcomings of clinicaltrials.gov as a database are important to recognize when considering the data presented here. Not all phase I trials, especially those conducted outside the US, may be registered, and our phase I data may underestimate the number of phase I candidates. Trials are required to be registered within 21 days of entering the first patient into the trial [7] , but not all sponsors meet this deadline. The data provided may not represent the entire universe of AD drug development [23] . We stopped entering new data into our database at a time that allowed submission, peer review, and publication; the data presented are a few months outof-date (data collection stopped January 5, 2017). Nevertheless, the FDA Modernization Act requires all trials to be registered and the International Committee of Medical Journal Editors requires trials to be registered to be eligible for publication [24] . The clinicaltrials.gov database is acceptably comprehensive-the most complete of any existing database-and a sound basis for drawing conclusions about AD drug development with the caveats mentioned here. Phase I is not the only source of compounds for phases II and III. Agents repurposed from other indications may have MOAs worthy of exploration in AD. Antihypertensive agents, statins, anti-inflammatory agents, calcium channel blockers, and agents with many other MOAs have been proposed as drugs with effects possibly useful in treating AD and can enter AD drug development pipelines at phase II or phase III [15, 19, 20] . Psychiatric agents are commonly developed in non-AD populations (e.g., major depressive disorder, schizophrenia) before being assessed in AD patients. Safety, tolerability, PK, and dosing observations of phase I may be available from studies conducted for the initial indication. Thus, the phase I observations provided here may not entirely forecast the compounds available for phase II and phase III. Nevertheless, the intellectual property challenges of repurposed compounds such as short-patent life limit biopharma interest in these agents, and only a modest number of repurposed agents are represented in the AD drug development pipeline (18 in phase II and six in phase III). The small number of phase I compounds is a concern for the overall health of the AD drug development pipeline.
A striking observation derived from these data is the long recruitment period anticipated for phase III DMTs. The anticipated recruitment period is often longer than the treatment period, and in many cases, these planned recruitment goals are not met [25, 26] . Prevention trials require more time to recruit than prodromal trials (133.5 weeks and 105.4 weeks, respectively) and mild-moderate AD trials (106.9 weeks). Slow recruitment is among the greatest challenges to efficiency of AD drug development [14] . This observation underlies recent efforts in the AD drug development arena to advance new methods for patient recruitment including electronic engagement of potential participants, creation of registries of candidate subjects, and providing transportation, neighborhood vans, and insurance-based referral mechanisms to facilitate subject recruitment and shorten drug development timelines [27, 28] .
A daunting conclusion from this review of clinicaltrials.gov is the large number of participants required to conduct the trials. Registered preclinical AD trials will require 8239 participants; trials of prodromal or prodromal/mild populations require 22,009 participants; trials of mild to moderate AD dementia are forecasted to require 22,253 participants; and trials in severe AD dementia will require 588 participants. In total, 54,073 participants will be required to complete the current AD trials. Trial recruitment is among the slowest and most expensive of all aspects of clinical trial conduct. The recruitment of such large numbers of participants will represent a substantial challenge to the system, and reforms are necessary to accelerate clinical trials and enhance recruitment [27, 28] .
BACE inhibitors are among the most common classes of molecules in the AD pipeline. Currently, there are 10 phase II or phase III trials involving BACE inhibitors ( Table 6 ). The pipeline for BACE inhibitors has emerged only recently largely because of the challenging structure-activity requirements for BACE inhibition; agents need to be large enough to block BACE's large active site, while at the same time, agents need to be small enough to pass through the bloodbrain barrier and lipophilic enough to enter endosomes where BACE is active [29] . Advances in small-molecule screening approaches have helped overcome these challenges and facilitated the entry of a number of BACE inhibitors into the pipeline [30] . All the BACE inhibitors currently in phases II and III trials are small molecules that demonstrate favorable PK when administered orally. The published results of phase I testing in both healthy participants and AD populations have demonstrated robust (45%-95%) reductions in CSF amyloid b protein (Ab) levels [31] . This degree of target engagement has not previously been documented with other anti-amyloid therapies leading some authors to posit that BACE inhibition represents the first true test of the amyloid hypothesis [32] . Based on strong biomarker data, some BACE inhibitors have bypassed phase II testing moving directly from phase I into phase III trials. As a result, little is known about the clinical efficacy or safety of longterm BACE inhibition. The first BACE inhibitor trial to be tested in phase III in an AD dementia population was recently terminated for the lack of efficacy [33] . Data from this and other studies will begin to answer the key questions regarding BACE inhibitors including when in the disease continuum should inhibition be started; what degree of amyloid inhibition is required for clinical benefit; does reduction in amyloid synthesis affect clinical progression; and are there unidentified safety concerns with long-term BACE inhibition?
Immunotherapies, especially monoclonal antibodies, are also well represented in the AD pipeline. There are currently 16 immunotherapy agents in 31 trials (Table 7) . This includes aducanumab, solanezumab, crenezumab, gantenerumab, and BAN2401. Immunotherapies target a variety of epitopes of Ab. Solanezumab targets soluble Ab; this agent recently failed to show a drug-placebo difference in a phase III trial. It was terminated as a candidate therapy for AD dementia [34] . It continues in prevention trials. Aducanumab targets multiple Ab species, has had an encouraging phase I/II trial, and is continuing in phase III [35] .
President Obama articulated a goal of cure or meaningful treatment for AD by the year 2025 [5, 36] . A recent analysis of AD drug development showed that it takes on average 13 years for a candidate treatment to move from laboratory to FDA review and 10 years for an agent to navigate the clinical development period from start of phase I to end of FDA review [37] . This means that under current circumstances, an agent must now be in phase II to possibly be approved by 2025 [5] . Although there are promising agents in the pipeline that could achieve this goal, it is clear that given the high rate of failure of AD drug development [38] , the aim of having a repertoire of agents that could respond comprehensively and individually to a patient's clinical circumstances within the 2025 timeframe is in jeopardy.
There are many factors contributing to the currently low rate of success of drug development for AD. The understanding of the biology of AD is incomplete, the emphasis on testing single therapies where combinations may be required, the few candidates entering phase I, the lack of predictive validity of animal models, lack of efficacy of candidate therapies, and the emergence of unacceptable side effects all limit successful treatment development. When clinical trials are considered, the slowness of recruitment, lack, until recently, of tests for diagnostic confirmation, the requirement to globalize trials to achieve sufficient recruitment at the expense of data variability, and the heterogeneity of AD may all contribute to the lack of success in trials.
Biomarkers can contribute substantially to drug development success [39] . In AD, there are few biomarkers given the myriad of affected processes; there are only a small number of target engagement biomarkers capable of giving an early readout on proof of pharmacology; there are no surrogate markers known to predict the clinical outcome; and no validated outcome biomarkers have been shown to correlate with clinical outcomes in a trial in support of disease modification. These circumstances disadvantage AD drug development and increase the failure rates, especially for proposed DMTs.
Symptomatic agents are an important part of the AD drug development pipeline. There are four cognitive enhancing agents and no agents targeting behavioral symptoms in phase I clinical trials. Phase II has eight cognitive enhancing agents and seven behavioral agents in trials, whereas phase III has three cognitive enhancing agents and seven behavioral agents. Together there are 15 cognitive enhancers and 14 agents targeting neuropsychiatric symptoms in the pipeline. This comprises 27% of the AD drug development pipeline. Treatments for neuropsychiatric symptoms are more likely than other classes of drugs to enter the pipeline in phase II or III after they have been assessed in phase I with the intent of treating a primary psychiatric illness.
The solution to the problem of the few agents in the AD drug development pipeline, the many challenges facing candidate therapies, and the slow speed of testing drugs can be partially addressed by increased funding. The NIH is critically involved in addressing AD as one of the major challenges to human health that currently goes unchecked. Investment in basic research will assist in identifying more targets and candidate compounds, whereas investment in translational research can help support clinical trials and improve trial methods. Federal small business loans can help fund enterprising new approaches to drug treatment; academic medical centers can spin off biotech startups around promising tests, biomarkers, and drugs; and venture capital can help support startup through early phases of development until larger biopharma companies are ready to take agents through the final most expensive phases of clinical trials and FDA review. Philanthropy and innovative approaches such as venture philanthropy may help accelerate AD drug discovery and development funding [40] . Biopharma sponsors 65.5% of all clinical trials and is the major economic force for drug development. All these financial instruments, however, are currently in place and are not sufficient to respond to the urgent need. New investment vehicles are needed, and some have been proposed such as private-federal bonds [41, 42] . Medicare and insurance companies who stand to benefit from improved health of the elderly should be engaged in funding conversations. New types of collaborations (e.g., between NIH and biopharma companies and between two biopharma companies) and consortia (e.g., the Alzheimer's Disease Neuroimaging Initiative) are increasing the financial feasibility of bearing the expense of AD drug development and enhancing the chance of success.
The need is great, the challenges many, the rewards high: this is the condition of AD drug development. Monitoring 
